Clinical Trial Update: Managed Access Programs for EXV811, Atrasentan

View source ↗

Summary

This release describes managed access programs for EXV811 (Atrasentan) in IgA nephropathy, provided by Novartis to eligible patients outside of formal trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Atrasentan (EXV811) (Atrasentan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: IgA Nephropathy | Status: AVAILABLE